The International Parkinson and Movement Disorder Society (MDS) gathers thousands of clinicians, researchers, trainees, and industry supporters to discuss the diagnosis and treatment of movement disorders on an annual basis.
Stewart Factor, MD: Long-Term Data on Apomorphine Sublingual Film in Parkinson
September 17th 2020The director of the Movement Disorders Program and Vance Lanier Chair of Neurology at Emory University School of Medicine gave his perspective on the interim findings of a long-term safety study of apomorphine sublingual film.
Apomorphine Sublingual Film Shows Long-Term Efficacy in OFF Episode Treatment
September 16th 2020The recently approved apomorphine sublingual film (Kynmobi; Sunovion) maintained efficacy over the long-term, with at least 74% of patients experiencing full ON within 30 minutes post-dose at each time point.
Essential Tremor Symptoms, Severity Improved With Cala Trio Neuromodulation Device
October 22nd 2019The wrist-worn wearable neuromodulation device for essential tremor was shown to be safe and efficacious in the PROSPECT trial, with more than 50% of patients experiencing a ≥50% improvement in tremor "power" or severity.
Mitsubishi Tanabe Reveals Phase 3 Study for Continuous Carbidopa/Levodopa in Parkinson Disease
September 26th 2019The clinical development of ND0612 includes 2 doses; a low dose for mid-stage Parkinson patients experiencing loss of motor control on oral therapy, and a high dose for severe disease in which oral drugs are no longer effective.
Amantadine ER Capsules for Dyskinesia Show Consistent Safety, Improved Motor Skills
September 25th 2019Data of amantadine (Gocovri, Adamas) extended-release tablets suggested that the therapy is, in fact, safe and tolerable with a unique pharmacokinetic profile, and results in significant improvements in dyskinesia for patients with Parkinson disease.